Dr. Soumava Mandal discusses the treatment options for neovascular age-related macular degeneration (NVAMD) that have emerged over time, including photocoagulation (1979), photodynamic therapy (PDT) (2001), and anti-VEGF drugs (2004). Key studies evaluated the efficacy of photocoagulation, PDT, pegaptanib, ranibizumab, bevacizumab, aflibercept, and brolucizumab in treating NVAMD. These studies demonstrated the benefits of anti-VEGF drugs over previous options, with ranibizumab and aflibercept approved for monthly or bi-monthly dosing based on visual acuity and OCT monitoring
This document discusses various vitreous substitutes and intraocular gases used to replace the vitreous humor after surgery. It describes the anatomy and composition of the natural vitreous and ideal properties for substitutes. Common substitutes discussed include gases like air, sulfur hexafluoride and perfluorocarbons; liquids like silicone oil, perfluorocarbon liquids and semi-fluorinated alkanes; and experimental polymers and implants. The document compares different options and provides details on how each works, associated complications, and appropriate uses.
1. Monocular elevation deficiency (MED), also known as double elevator palsy, is characterized by an inability to elevate one eye in all fields of gaze, resulting in hypotropia of the affected eye.
2. The condition can be congenital or acquired, with causes including superior rectus palsy, inferior rectus restriction, and supranuclear lesions.
3. Surgical management of MED depends on forced duction test results and may include inferior rectus recession, superior rectus resection, or Knapp's procedure to transpose the horizontal rectus muscles. The goal is to improve eye position and increase binocular vision.
This document discusses cystoid macular edema (CME), including its pathogenesis, etiology, associated ocular conditions, manifestations, diagnosis and testing. Specifically, it focuses on pseudophakic or Irvine-Gass syndrome CME, which can occur after cataract surgery. The summary discusses how CME results from fluid accumulation in the retina, its appearance on fluorescein angiography, risk factors for pseudophakic CME like vitreous loss during surgery, and how it is diagnosed using techniques like optical coherence tomography.
Serous choroidal detachment occurs when fluid accumulates between the choroid and sclera, lifting the choroid. It is often related to low intraocular pressure after surgery or trauma. Hemorrhagic choroidal detachment results from rupture of short posterior ciliary arteries due to trauma, surgery, or increased pressure. Ultrasound shows a smooth dome-shaped elevation and OCT may show retinal pigment epithelium thickening. Management includes cycloplegia, corticosteroids, increasing intraocular pressure, and sometimes choroidal drainage surgery. Prognosis depends on extent of detachment and hemorrhage, with limited detachments having better outcomes.
Dry age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among people over 65. It is characterized by the breakdown and loss of cells in the macula due to aging and can be categorized as either dry or wet AMD. Dry AMD accounts for 90% of cases and results in gradual vision loss over time due to buildup of drusen and development of geographic atrophy in the macula. Diagnosis is based on the presence of soft or large drusen, pigmentary abnormalities, and atrophy seen on examination and imaging like OCT. There is no cure for dry AMD and vision loss progresses slowly, resulting in central blind spots.
Pigment epithelial detachment (PED) occurs when the retinal pigment epithelium separates from the underlying Bruch's membrane, usually due to fluid accumulation. There are several types of PED including drusenoid, serous, and vascularized PEDs. PEDs can be caused by conditions like age-related macular degeneration and central serous choroidopathy. Optical coherence tomography is used to characterize the type and contents of the PED. Treatment depends on the specific cause and characteristics of the PED.
This document discusses using optical coherence tomography (OCT) to analyze the macula, retinal nerve fiber layer (RNFL), and optic nerve head in patients with glaucoma or suspected glaucoma. It describes how OCT can measure macular thickness, RNFL thickness, and optic disc parameters. Five case studies are presented showing how structural changes seen on OCT correlate with functional defects on visual field tests or clinical findings. The document concludes by mentioning Doppler OCT may help understand the role of blood flow in glaucoma and other optic neuropathies.
Vitreous substitutes are substances used during vitreoretinal surgery to re-establish intraocular volume, assist with separating membranes from the retina, and manipulate and flatten detached retina. They are also used postoperatively as long-term tamponading agents to maintain the retina in apposition. Common vitreous substitutes used include balanced salt solution, air, viscoelastic fluids, silicone liquid, and perfluorocarbon liquids. Gases such as air, SF6, and C3F8 are employed during retinal detachment surgery to provide internal tamponade and are chosen based on their duration, expansion properties, and buoyancy effects. Complications can include increased intraocular pressure, lens opac
This document discusses various vitreous substitutes and intraocular gases used to replace the vitreous humor after surgery. It describes the anatomy and composition of the natural vitreous and ideal properties for substitutes. Common substitutes discussed include gases like air, sulfur hexafluoride and perfluorocarbons; liquids like silicone oil, perfluorocarbon liquids and semi-fluorinated alkanes; and experimental polymers and implants. The document compares different options and provides details on how each works, associated complications, and appropriate uses.
1. Monocular elevation deficiency (MED), also known as double elevator palsy, is characterized by an inability to elevate one eye in all fields of gaze, resulting in hypotropia of the affected eye.
2. The condition can be congenital or acquired, with causes including superior rectus palsy, inferior rectus restriction, and supranuclear lesions.
3. Surgical management of MED depends on forced duction test results and may include inferior rectus recession, superior rectus resection, or Knapp's procedure to transpose the horizontal rectus muscles. The goal is to improve eye position and increase binocular vision.
This document discusses cystoid macular edema (CME), including its pathogenesis, etiology, associated ocular conditions, manifestations, diagnosis and testing. Specifically, it focuses on pseudophakic or Irvine-Gass syndrome CME, which can occur after cataract surgery. The summary discusses how CME results from fluid accumulation in the retina, its appearance on fluorescein angiography, risk factors for pseudophakic CME like vitreous loss during surgery, and how it is diagnosed using techniques like optical coherence tomography.
Serous choroidal detachment occurs when fluid accumulates between the choroid and sclera, lifting the choroid. It is often related to low intraocular pressure after surgery or trauma. Hemorrhagic choroidal detachment results from rupture of short posterior ciliary arteries due to trauma, surgery, or increased pressure. Ultrasound shows a smooth dome-shaped elevation and OCT may show retinal pigment epithelium thickening. Management includes cycloplegia, corticosteroids, increasing intraocular pressure, and sometimes choroidal drainage surgery. Prognosis depends on extent of detachment and hemorrhage, with limited detachments having better outcomes.
Dry age-related macular degeneration (AMD) is the leading cause of irreversible vision loss among people over 65. It is characterized by the breakdown and loss of cells in the macula due to aging and can be categorized as either dry or wet AMD. Dry AMD accounts for 90% of cases and results in gradual vision loss over time due to buildup of drusen and development of geographic atrophy in the macula. Diagnosis is based on the presence of soft or large drusen, pigmentary abnormalities, and atrophy seen on examination and imaging like OCT. There is no cure for dry AMD and vision loss progresses slowly, resulting in central blind spots.
Pigment epithelial detachment (PED) occurs when the retinal pigment epithelium separates from the underlying Bruch's membrane, usually due to fluid accumulation. There are several types of PED including drusenoid, serous, and vascularized PEDs. PEDs can be caused by conditions like age-related macular degeneration and central serous choroidopathy. Optical coherence tomography is used to characterize the type and contents of the PED. Treatment depends on the specific cause and characteristics of the PED.
This document discusses using optical coherence tomography (OCT) to analyze the macula, retinal nerve fiber layer (RNFL), and optic nerve head in patients with glaucoma or suspected glaucoma. It describes how OCT can measure macular thickness, RNFL thickness, and optic disc parameters. Five case studies are presented showing how structural changes seen on OCT correlate with functional defects on visual field tests or clinical findings. The document concludes by mentioning Doppler OCT may help understand the role of blood flow in glaucoma and other optic neuropathies.
Vitreous substitutes are substances used during vitreoretinal surgery to re-establish intraocular volume, assist with separating membranes from the retina, and manipulate and flatten detached retina. They are also used postoperatively as long-term tamponading agents to maintain the retina in apposition. Common vitreous substitutes used include balanced salt solution, air, viscoelastic fluids, silicone liquid, and perfluorocarbon liquids. Gases such as air, SF6, and C3F8 are employed during retinal detachment surgery to provide internal tamponade and are chosen based on their duration, expansion properties, and buoyancy effects. Complications can include increased intraocular pressure, lens opac
The document discusses Fourth Nerve Palsy (SOP), which causes weakness of the superior oblique muscle. It describes the anatomy of the fourth cranial nerve and the effects of SOP, including ipsilateral hypertropia that increases in opposite gaze. Common causes are trauma, vascular issues like hypertension, and diabetes. Clinical findings are outlined, along with classification systems. Management involves investigating for underlying causes, using prisms for small deviations, and surgery like weakening overacting muscles for large deviations. Surgical techniques are provided to address specific muscle weaknesses or torsion.
This document summarizes several landmark clinical trials related to diabetic retinopathy. It discusses trials evaluating metabolic control like the DCCT and UKPDS, laser photocoagulation trials like DRS and ETDRS, vitrectomy trials like DRVS, and recent anti-VEGF trials. It also summarizes protocols from the Diabetic Retinopathy Clinical Research Network evaluating treatments for diabetic macular edema and proliferative diabetic retinopathy.
This document discusses intermittent exotropia, including its theories, presentation, examination, classification, treatment, and surgical management. The key points are:
1. Intermittent exotropia is thought to be caused by an imbalance between convergence and divergence muscles. It typically begins as exophoria in infancy and progresses to intermittent exotropia.
2. Examination includes measuring the deviation at distance and near with and without lenses to classify the type. Non-surgical treatment aims to improve vergence control through patching, lenses, and orthoptics.
3. Surgical treatment is indicated for deviations over 20 prism diopters, worsening control, or failure of conservative therapy.
This document discusses corneal collagen cross linking (C3R), a treatment for keratoconus. It begins by describing keratoconus and its symptoms. It then discusses the original C3R protocol developed by Seiler and Spoerl, which involves removing the corneal epithelium, soaking the cornea in riboflavin, and exposing it to UV light. Modifications to the protocol aim to reduce complications by using higher irradiance for less time, different riboflavin delivery methods, and leaving the epithelium intact. Studies show C3R increases corneal collagen bonds and rigidity while halting keratoconus progression in most cases. Contraindications and post-op care are also outlined
This document discusses various complications that can occur after keratoplasty (corneal transplantation). It summarizes early post-operative complications such as shallow anterior chamber, wound leak, iris incarceration, wound dehiscence, and suture-related problems. It also discusses late complications that can occur months or years after surgery, including graft rejection, infectious crystalline keratopathy, corneal membranes, cataract, astigmatism, glaucoma, and recurrence of the original recipient corneal disorder. For each complication, the document provides details on causes, risk factors, clinical features, prevention strategies and management approaches.
This document provides information about optical biometry and the IOL Master device. It discusses the principles and history of optical interferometry, intended uses of the IOL Master including axial length measurement, corneal curvature measurement, and IOL power calculation. Screen layouts and measurements taken by the IOL Master are described. Advantages include highly accurate and non-contact measurements, while limitations include inability to measure in cases of severe media opacities or poor patient cooperation.
This document discusses choroidal neovascularization (CNV), which is the abnormal growth of blood vessels from the choroid into the retina or subretinal space. It is a cause of vision loss and the main feature of exudative age-related macular degeneration. The document defines CNV and lists various conditions that can cause it. It then focuses on CNV caused by age-related macular degeneration, covering risk factors, pathogenesis, symptoms, diagnostic findings on fluorescein angiography and OCT, and various treatment options including anti-VEGF drugs, photodynamic therapy, and laser photocoagulation.
This document summarizes recent advances in treating age-related macular degeneration (AMD). It discusses new drugs that aim to prevent retinal damage or slow AMD progression by inhibiting angiogenesis, inflammation, the complement pathway, oxidative stress, and retinal toxin accumulation. It also describes surgeries like maculoplasty and bionic eye implants, as well as rehabilitation techniques and low vision aids. Promising new drug classes discussed include anti-angiogenics, complement inhibitors, neurotrophic factors, and antioxidants.
This document discusses branch retinal vein occlusion (BRVO), including its pathogenesis, clinical features, complications, investigations, and management. BRVO is caused by obstruction of one of the retinal veins, usually at the arteriovenous crossing point. It can lead to macular edema, neovascularization, vitreous hemorrhage, and retinal detachment. Treatment involves anti-VEGF injections, steroids, laser photocoagulation, and occasionally surgery. Several clinical trials have evaluated therapies for BRVO, finding that anti-VEGF drugs and steroids reduce macular edema but laser provides little additional benefit when combined with anti-VEGF treatment.
This document discusses the diagnosis of pre-perimetric glaucoma. It begins by defining pre-perimetric glaucoma as optic nerve abnormalities seen on structural tests with normal visual fields. It then discusses the need for early diagnosis before functional changes occur. Various functional tests are described like standard automated perimetry, short wavelength automated perimetry, frequency doubling technology, and others. Structural tests like confocal scanning laser ophthalmoscopy, optical coherence tomography, and their principles are summarized.
This document provides an overview of macular holes, including:
- Classification into primary (idiopathic) and secondary holes. Primary holes are caused by vitreous traction while secondary have other causes like trauma.
- Stages of macular hole formation based on Gass classification from early detachment to full thickness hole.
- Surgical treatment involves vitrectomy to relieve traction along with internal limiting membrane peeling which has good outcomes in improving vision.
- Differential diagnosis includes epiretinal membranes and pseudoholes which have different presentations and prognoses.
Iol power calculation in pediatric patientsAnisha Rathod
- Many factors affect intraocular lens (IOL) power calculation in pediatric patients including age at surgery, laterality, amblyopia, axial length, keratometry, and expected myopic shift due to ongoing eye growth.
- Normal eye development involves rapid growth of the axial length and changes in lens power in the first years of life.
- Target postoperative refraction must account for this myopic shift and generally involves undercorrecting more in younger patients.
- Accurate biometry using immersion ultrasound or optical techniques is important to minimize errors from corneal compression.
- Formulas, IOL type and position can further influence outcomes.
Choroidal neovascular membranes (CNVM)Md Riyaj Ali
Choroidal neovascularization (CNV) involves the abnormal growth of new blood vessels from the choroid layer of the eye through Bruch's membrane. This can cause vision loss and is a common cause of wet macular degeneration. CNV occurs due to alterations in Bruch's membrane and high levels of vascular endothelial growth factor. It is classified based on its location relative to the retinal pigment epithelium and fovea. Symptoms include sudden vision loss and visual distortions. CNV is diagnosed through imaging like optical coherence tomography and fluorescein angiography and treated with injections of anti-VEGF drugs to inhibit blood vessel growth.
The document discusses key findings from several DRCR protocols:
1. Protocol B compared IV steroids and laser for DME and found steroids were not superior and had more adverse events than laser.
2. Protocol I found ranibizumab with prompt or deferred laser had superior vision outcomes compared to laser alone for DME. TA plus laser had similar results to ranibizumab.
3. Protocol S showed ranibizumab was non-inferior to PRP for PDR and had better vision outcomes and less DME and progression than PRP. However, long term stability is still unknown.
4. The PROTEUS study found ranibizumab plus PRP was more
This document discusses potential complications of trabeculectomy, both intraoperative and postoperative. Intraoperative complications include buttonholing of the conjunctiva, scleral flap tears, lens injury, vitreous prolapse, hyphema, and suprachoroidal hemorrhage. Postoperative complications can be early such as hypotony, elevated intraocular pressure, choroidal effusions or late such as thin blebs, infections, and cataracts. Management strategies are provided for addressing complications depending on the specific issue.
This document discusses the use of lasers in the treatment of glaucoma. It begins by introducing different types of lasers used, including Nd:YAG lasers. It then covers specific laser procedures for glaucoma such as laser iridotomy to relieve pupillary block, laser iridoplasty to modify the iris, and laser trabeculoplasty to increase outflow. It compares argon laser trabeculoplasty to selective laser trabeculoplasty. The document also discusses laser techniques for angle closure glaucoma, post-operative treatment, and cyclophotocoagulation to reduce aqueous production. Throughout, it provides details on laser parameters and outcomes of these procedures.
This document summarizes several studies and clinical trials related to the treatment of diabetic retinopathy and diabetic macular edema. It discusses the Diabetic Retinopathy Study (DRS) and Early Treatment Diabetic Retinopathy Study (ETDRS) which established laser photocoagulation as the standard treatment for proliferative diabetic retinopathy and diabetic macular edema. It also summarizes the Diabetic Retinopathy Clinical Research Network (DRCR.Net) which conducted several clinical trials comparing treatments for diabetic macular edema such as anti-VEGF injections and laser photocoagulation. The document provides high-level overviews of many landmark studies that helped advance the treatment of diabetic eye disease.
This document discusses sources and management of postoperative astigmatism after cataract surgery. It notes that the main sources of astigmatism are preexisting astigmatism, incision characteristics like length and location, and suture characteristics like type, tension, and placement. Larger or superior incisions, and sutures that degrade quickly or are placed unevenly, tend to cause more astigmatism. Managing factors like smaller incisions, frown-shape cuts, posterior placement, uniform tension, and non-degrading suture material can help minimize postoperative astigmatism. Precise suture removal timing and selective cutting can further refine astigmatism outcomes after surgery.
Dissociated vertical deviation (DVD) is a condition where one eye turns upward when the other eye fixes. It typically presents between ages 2-5 years and is often associated with infantile esotropia. DVD violates the rules of ocular motility as the deviating eye does not make a rapid movement to refixate. Measurement and tests like Bielschowsky's phenomenon and red glass testing help differentiate DVD from other vertical deviations. Treatment involves observation, encouraging bifixation, or surgery like superior rectus recession if the deviation is increasing. It is important to differentiate DVD from inferior oblique overaction.
The document discusses patterns of strabismus, specifically the A pattern and V pattern. The A pattern involves relative convergence on upgaze and divergence on downgaze, while the V pattern is the opposite with relative divergence on upgaze and convergence on downgaze. Variants include the X, Y, lambda, and diamond patterns. The etiology of these patterns involves dysfunction of the horizontal, vertical, or oblique eye muscles. Clinical features may include anomalous head posture, amblyopia, and abnormal retinal correspondence. Diagnosis involves measuring alignment in upgaze and downgaze while preventing accommodation.
Recent advances in treatment of DME include:
1) Frequency doubled Nd:YAG and micropulse diode lasers can treat DME with less damage to the retina compared to traditional lasers.
2) Steroid implants like ILUVIEN and Ozurdex have shown benefits for DME, with ILUVIEN maintaining vision gains over 3 years and Ozurdex benefits lasting 6 months.
3) Ranibizumab injections with or without prompt laser provide mean vision improvements of 9-10 letters over 1 year for DME treatment, with sustained benefits over 2 years.
This document discusses the role of anti-VEGF therapy in the management of neovascular age-related macular degeneration (AMD). It outlines various treatment options for neovascular AMD including laser photocoagulation, photodynamic therapy, and anti-VEGF therapy. Anti-VEGF agents like ranibizumab, bevacizumab, and aflibercept are effective at inhibiting VEGF and stabilizing vision in neovascular AMD patients. Clinical trials demonstrate the superiority of monthly ranibizumab injections over sham treatment or verteporfin photodynamic therapy. While bevacizumab has equivalent visual outcomes to ranibizumab, it is not FDA approved and has higher rates of systemic side effects
The document discusses Fourth Nerve Palsy (SOP), which causes weakness of the superior oblique muscle. It describes the anatomy of the fourth cranial nerve and the effects of SOP, including ipsilateral hypertropia that increases in opposite gaze. Common causes are trauma, vascular issues like hypertension, and diabetes. Clinical findings are outlined, along with classification systems. Management involves investigating for underlying causes, using prisms for small deviations, and surgery like weakening overacting muscles for large deviations. Surgical techniques are provided to address specific muscle weaknesses or torsion.
This document summarizes several landmark clinical trials related to diabetic retinopathy. It discusses trials evaluating metabolic control like the DCCT and UKPDS, laser photocoagulation trials like DRS and ETDRS, vitrectomy trials like DRVS, and recent anti-VEGF trials. It also summarizes protocols from the Diabetic Retinopathy Clinical Research Network evaluating treatments for diabetic macular edema and proliferative diabetic retinopathy.
This document discusses intermittent exotropia, including its theories, presentation, examination, classification, treatment, and surgical management. The key points are:
1. Intermittent exotropia is thought to be caused by an imbalance between convergence and divergence muscles. It typically begins as exophoria in infancy and progresses to intermittent exotropia.
2. Examination includes measuring the deviation at distance and near with and without lenses to classify the type. Non-surgical treatment aims to improve vergence control through patching, lenses, and orthoptics.
3. Surgical treatment is indicated for deviations over 20 prism diopters, worsening control, or failure of conservative therapy.
This document discusses corneal collagen cross linking (C3R), a treatment for keratoconus. It begins by describing keratoconus and its symptoms. It then discusses the original C3R protocol developed by Seiler and Spoerl, which involves removing the corneal epithelium, soaking the cornea in riboflavin, and exposing it to UV light. Modifications to the protocol aim to reduce complications by using higher irradiance for less time, different riboflavin delivery methods, and leaving the epithelium intact. Studies show C3R increases corneal collagen bonds and rigidity while halting keratoconus progression in most cases. Contraindications and post-op care are also outlined
This document discusses various complications that can occur after keratoplasty (corneal transplantation). It summarizes early post-operative complications such as shallow anterior chamber, wound leak, iris incarceration, wound dehiscence, and suture-related problems. It also discusses late complications that can occur months or years after surgery, including graft rejection, infectious crystalline keratopathy, corneal membranes, cataract, astigmatism, glaucoma, and recurrence of the original recipient corneal disorder. For each complication, the document provides details on causes, risk factors, clinical features, prevention strategies and management approaches.
This document provides information about optical biometry and the IOL Master device. It discusses the principles and history of optical interferometry, intended uses of the IOL Master including axial length measurement, corneal curvature measurement, and IOL power calculation. Screen layouts and measurements taken by the IOL Master are described. Advantages include highly accurate and non-contact measurements, while limitations include inability to measure in cases of severe media opacities or poor patient cooperation.
This document discusses choroidal neovascularization (CNV), which is the abnormal growth of blood vessels from the choroid into the retina or subretinal space. It is a cause of vision loss and the main feature of exudative age-related macular degeneration. The document defines CNV and lists various conditions that can cause it. It then focuses on CNV caused by age-related macular degeneration, covering risk factors, pathogenesis, symptoms, diagnostic findings on fluorescein angiography and OCT, and various treatment options including anti-VEGF drugs, photodynamic therapy, and laser photocoagulation.
This document summarizes recent advances in treating age-related macular degeneration (AMD). It discusses new drugs that aim to prevent retinal damage or slow AMD progression by inhibiting angiogenesis, inflammation, the complement pathway, oxidative stress, and retinal toxin accumulation. It also describes surgeries like maculoplasty and bionic eye implants, as well as rehabilitation techniques and low vision aids. Promising new drug classes discussed include anti-angiogenics, complement inhibitors, neurotrophic factors, and antioxidants.
This document discusses branch retinal vein occlusion (BRVO), including its pathogenesis, clinical features, complications, investigations, and management. BRVO is caused by obstruction of one of the retinal veins, usually at the arteriovenous crossing point. It can lead to macular edema, neovascularization, vitreous hemorrhage, and retinal detachment. Treatment involves anti-VEGF injections, steroids, laser photocoagulation, and occasionally surgery. Several clinical trials have evaluated therapies for BRVO, finding that anti-VEGF drugs and steroids reduce macular edema but laser provides little additional benefit when combined with anti-VEGF treatment.
This document discusses the diagnosis of pre-perimetric glaucoma. It begins by defining pre-perimetric glaucoma as optic nerve abnormalities seen on structural tests with normal visual fields. It then discusses the need for early diagnosis before functional changes occur. Various functional tests are described like standard automated perimetry, short wavelength automated perimetry, frequency doubling technology, and others. Structural tests like confocal scanning laser ophthalmoscopy, optical coherence tomography, and their principles are summarized.
This document provides an overview of macular holes, including:
- Classification into primary (idiopathic) and secondary holes. Primary holes are caused by vitreous traction while secondary have other causes like trauma.
- Stages of macular hole formation based on Gass classification from early detachment to full thickness hole.
- Surgical treatment involves vitrectomy to relieve traction along with internal limiting membrane peeling which has good outcomes in improving vision.
- Differential diagnosis includes epiretinal membranes and pseudoholes which have different presentations and prognoses.
Iol power calculation in pediatric patientsAnisha Rathod
- Many factors affect intraocular lens (IOL) power calculation in pediatric patients including age at surgery, laterality, amblyopia, axial length, keratometry, and expected myopic shift due to ongoing eye growth.
- Normal eye development involves rapid growth of the axial length and changes in lens power in the first years of life.
- Target postoperative refraction must account for this myopic shift and generally involves undercorrecting more in younger patients.
- Accurate biometry using immersion ultrasound or optical techniques is important to minimize errors from corneal compression.
- Formulas, IOL type and position can further influence outcomes.
Choroidal neovascular membranes (CNVM)Md Riyaj Ali
Choroidal neovascularization (CNV) involves the abnormal growth of new blood vessels from the choroid layer of the eye through Bruch's membrane. This can cause vision loss and is a common cause of wet macular degeneration. CNV occurs due to alterations in Bruch's membrane and high levels of vascular endothelial growth factor. It is classified based on its location relative to the retinal pigment epithelium and fovea. Symptoms include sudden vision loss and visual distortions. CNV is diagnosed through imaging like optical coherence tomography and fluorescein angiography and treated with injections of anti-VEGF drugs to inhibit blood vessel growth.
The document discusses key findings from several DRCR protocols:
1. Protocol B compared IV steroids and laser for DME and found steroids were not superior and had more adverse events than laser.
2. Protocol I found ranibizumab with prompt or deferred laser had superior vision outcomes compared to laser alone for DME. TA plus laser had similar results to ranibizumab.
3. Protocol S showed ranibizumab was non-inferior to PRP for PDR and had better vision outcomes and less DME and progression than PRP. However, long term stability is still unknown.
4. The PROTEUS study found ranibizumab plus PRP was more
This document discusses potential complications of trabeculectomy, both intraoperative and postoperative. Intraoperative complications include buttonholing of the conjunctiva, scleral flap tears, lens injury, vitreous prolapse, hyphema, and suprachoroidal hemorrhage. Postoperative complications can be early such as hypotony, elevated intraocular pressure, choroidal effusions or late such as thin blebs, infections, and cataracts. Management strategies are provided for addressing complications depending on the specific issue.
This document discusses the use of lasers in the treatment of glaucoma. It begins by introducing different types of lasers used, including Nd:YAG lasers. It then covers specific laser procedures for glaucoma such as laser iridotomy to relieve pupillary block, laser iridoplasty to modify the iris, and laser trabeculoplasty to increase outflow. It compares argon laser trabeculoplasty to selective laser trabeculoplasty. The document also discusses laser techniques for angle closure glaucoma, post-operative treatment, and cyclophotocoagulation to reduce aqueous production. Throughout, it provides details on laser parameters and outcomes of these procedures.
This document summarizes several studies and clinical trials related to the treatment of diabetic retinopathy and diabetic macular edema. It discusses the Diabetic Retinopathy Study (DRS) and Early Treatment Diabetic Retinopathy Study (ETDRS) which established laser photocoagulation as the standard treatment for proliferative diabetic retinopathy and diabetic macular edema. It also summarizes the Diabetic Retinopathy Clinical Research Network (DRCR.Net) which conducted several clinical trials comparing treatments for diabetic macular edema such as anti-VEGF injections and laser photocoagulation. The document provides high-level overviews of many landmark studies that helped advance the treatment of diabetic eye disease.
This document discusses sources and management of postoperative astigmatism after cataract surgery. It notes that the main sources of astigmatism are preexisting astigmatism, incision characteristics like length and location, and suture characteristics like type, tension, and placement. Larger or superior incisions, and sutures that degrade quickly or are placed unevenly, tend to cause more astigmatism. Managing factors like smaller incisions, frown-shape cuts, posterior placement, uniform tension, and non-degrading suture material can help minimize postoperative astigmatism. Precise suture removal timing and selective cutting can further refine astigmatism outcomes after surgery.
Dissociated vertical deviation (DVD) is a condition where one eye turns upward when the other eye fixes. It typically presents between ages 2-5 years and is often associated with infantile esotropia. DVD violates the rules of ocular motility as the deviating eye does not make a rapid movement to refixate. Measurement and tests like Bielschowsky's phenomenon and red glass testing help differentiate DVD from other vertical deviations. Treatment involves observation, encouraging bifixation, or surgery like superior rectus recession if the deviation is increasing. It is important to differentiate DVD from inferior oblique overaction.
The document discusses patterns of strabismus, specifically the A pattern and V pattern. The A pattern involves relative convergence on upgaze and divergence on downgaze, while the V pattern is the opposite with relative divergence on upgaze and convergence on downgaze. Variants include the X, Y, lambda, and diamond patterns. The etiology of these patterns involves dysfunction of the horizontal, vertical, or oblique eye muscles. Clinical features may include anomalous head posture, amblyopia, and abnormal retinal correspondence. Diagnosis involves measuring alignment in upgaze and downgaze while preventing accommodation.
Recent advances in treatment of DME include:
1) Frequency doubled Nd:YAG and micropulse diode lasers can treat DME with less damage to the retina compared to traditional lasers.
2) Steroid implants like ILUVIEN and Ozurdex have shown benefits for DME, with ILUVIEN maintaining vision gains over 3 years and Ozurdex benefits lasting 6 months.
3) Ranibizumab injections with or without prompt laser provide mean vision improvements of 9-10 letters over 1 year for DME treatment, with sustained benefits over 2 years.
This document discusses the role of anti-VEGF therapy in the management of neovascular age-related macular degeneration (AMD). It outlines various treatment options for neovascular AMD including laser photocoagulation, photodynamic therapy, and anti-VEGF therapy. Anti-VEGF agents like ranibizumab, bevacizumab, and aflibercept are effective at inhibiting VEGF and stabilizing vision in neovascular AMD patients. Clinical trials demonstrate the superiority of monthly ranibizumab injections over sham treatment or verteporfin photodynamic therapy. While bevacizumab has equivalent visual outcomes to ranibizumab, it is not FDA approved and has higher rates of systemic side effects
Retinal vein occlusions are a common retinal vascular disease. Studies have shown anti-VEGF drugs like ranibizumab and aflibercept to be effective treatments for macular edema due to retinal vein occlusions, improving vision and reducing edema. Dexamethasone implants have also shown short term benefits but effects are not sustained long term and frequent injections are needed to maintain benefits. Long term studies of anti-VEGF drugs demonstrate their effectiveness can be maintained with periodic injections over several years.
1) The document discusses various treatment options for central retinal vein occlusion (CRVO) including anti-VEGF drugs such as ranibizumab, aflibercept, and bevacizumab as well as steroid implants like dexamethasone and triamcinolone.
2) Clinical trials showed anti-VEGF drugs provided significant vision gains compared to observation alone, while results were mixed for other options like photocoagulation and steroids.
3) Long-term follow up data demonstrated the need for ongoing treatment to maintain vision gains in CRVO patients, with some achieving resolution of edema and excellent outcomes.
Retinal vein occlusions are the second most common retinal vascular disease after diabetic retinopathy. Several studies have evaluated treatments for macular edema secondary to retinal vein occlusions. Anti-VEGF drugs like ranibizumab, aflibercept, and bevacizumab have been shown to significantly improve visual acuity and reduce macular thickness compared to observation or laser, with benefits maintained over 1-2 years. Dexamethasone intravitreal implants also provide initial benefits but effects are not sustained long-term and are associated with increased risks of cataract and elevated intraocular pressure.
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasaddrsomduttprasad
My Presentation at the 29th Annual Meeting of APACRS 2016 held from July 27-30, 2016 at Bali Dua Convention Center, Bali, Indonesia. Visit http://bit.ly/1ShlIdD for event details and video of the presentation.
This document discusses diabetic macular edema (DME), its causes and prevalence, current treatments, and evidence for the use of ranibizumab (Lucentis) in the treatment of DME. Some key points:
- DME is the main cause of central vision loss in diabetic retinopathy and can affect 10-25% of diabetics depending on type of diabetes and insulin use.
- Current treatments include controlling blood sugar, blood pressure, lipids as well as laser photocoagulation and pharmacologic therapies like steroids and anti-VEGF drugs.
- Studies like RESOLVE, READ-2 and DRCR.net trials showed ranibizumab led to significant gains in
This document discusses diabetic macular edema (DME), its causes and prevalence, current treatments, and evidence for the use of ranibizumab (Lucentis) in the treatment of DME. Some key points:
- DME is the main cause of central vision loss in diabetic retinopathy and can affect 10-25% of diabetics depending on type of diabetes and insulin use.
- Current treatments include controlling blood sugar, blood pressure, lipids, and ocular treatments like laser photocoagulation and pharmacologic therapies like steroids and anti-VEGF drugs.
- Studies like RESOLVE, READ-2, and RESTORE showed ranibizumab significantly improved visual
- This study compared the efficacy of ranibizumab injections plus panretinal photocoagulation (PRP) versus PRP alone for the treatment of high-risk proliferative diabetic retinopathy over 12 months.
- The primary outcome was regression of neovascularization, which occurred in 92.7% of eyes receiving ranibizumab+PRP and 70.5% of eyes receiving PRP alone, a statistically significant difference.
- Secondary outcomes also favored the combination treatment, including a higher rate of complete neovascularization regression, shorter time to complete regression, and thinner macular retinal thickness at intermediate visits.
Retina diseases by non retina specialistSeshu Gosala
This document summarizes key information about managing retinal disorders like age-related macular degeneration (AMD). It discusses the evolution of treatment regimens for AMD from monthly injections to treat-and-extend approaches. It also reviews important clinical trials on AMD treatments and imaging techniques like OCT and OCT-A. Overall, the document emphasizes that AMD requires long-term, individualized management to optimize outcomes while minimizing treatment burden.
1) The document discusses resistance to anti-VEGF injections for wet age-related macular degeneration (wAMD), including treatment regimens, therapy failure, and treatment switching.
2) It finds that resistance can occur through tachyphylaxis or tolerance, and that switching therapy from ranibizumab to aflibercept or bevacizumab can be effective for patients who do not respond to or lose response to ranibizumab over time.
3) A trial switching patients to aflibercept who were incomplete responders to multiple ranibizumab injections found mean central subfield thickness decreased by 27.3 μm and 15.6% of eyes had a decrease in thickness of
Eylea (aflibercept) is an effective treatment for neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) that requires fewer injections than alternatives like ranibizumab. It has a stronger binding affinity to VEGF than ranibizumab and bevacizumab, and can suppress VEGF for longer. Clinical trials showed patients receiving Eylea achieved vision gains and needed on average 5 fewer injections over 2 years compared to monthly ranibizumab. Eylea is also highly effective for occult CNV, PED, and has shown vision gains maintained over 2 years in PCV with more than 30% of patients achieving complete polyp
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trialLaxmi Eye Institute
Ranibizumab injections led to improved visual acuity and resolution of macular edema compared to sham injections in patients with central retinal vein occlusion. At 6 months, patients receiving 0.3 mg or 0.5 mg ranibizumab were twice as likely to have a visual acuity of 20/40 or better compared to the sham group. Ranibizumab also significantly reduced central foveal thickness within 7 days, suggesting retinal edema in CRVO is primarily VEGF-mediated. While ranibizumab was effective, longer term studies are needed to determine optimal duration of treatment and benefits in less severe cases.
Challenging cases in diabetic retinopathy - DME protocolRiyad Banayot
This case report describes two challenging cases of diabetic retinopathy and macular edema.
Case 1 involves a 59-year-old man with type 2 diabetes and history of severe non-proliferative diabetic retinopathy and macular edema in both eyes. He was initially treated with focal/grid laser in one eye and intravitreal injections in the other eye. Over several years of follow up and treatment with additional injections as needed, his vision stabilized around 6/6 in both eyes despite persistent edema.
Case 2 involves an 83-year-old man with type 2 diabetes, proliferative diabetic retinopathy status post panretinal photocoagulation in one eye, and history of macular edema
This document provides an overview of diabetic macular edema (DME) and its treatment. It discusses the results of major clinical trials that established standards of care. The Early Treatment Diabetic Retinopathy Study (ETDRS) first demonstrated that focal laser photocoagulation can reduce vision loss from DME. However, many patients still lose vision with laser alone. Recent studies show anti-VEGF agents like ranibizumab are now the standard treatment, providing better outcomes than laser. Clinical trials found ranibizumab improves vision in DME and fewer injections are needed over time using PRN regimens. While laser remains an option, anti-VEGF agents lead to greater vision gains and have replaced laser
Brolucizumab is a humanized monoclonal antibody fragment that binds to and inhibits VEGF-A. It has a smaller molecular weight and longer half-life than ranibizumab and bevacizumab. Studies have shown brolucizumab to be non-inferior to aflibercept in treating wet AMD and DME, with some anatomical outcomes favoring brolucizumab. The risk of intraocular inflammation is higher with brolucizumab compared to aflibercept. Case reports have demonstrated effectiveness of brolucizumab in recalcitrant macular edema from CRVO and in treating PCV.
The DRCR.net Protocol S study compared the safety and efficacy of panretinal photocoagulation (PRP) versus intravitreal injections of ranibizumab 0.5 mg for the treatment of proliferative diabetic retinopathy (PDR) without prior PRP and with vision of at least 20/30. Over two years, ranibizumab provided superior visual acuity gains, less visual field loss, and fewer vitrectomies compared to PRP. However, long-term outcomes beyond two years are still unknown, and PRP may provide more stable regression of PDR over 15 years without need for further treatment. So while ranibizumab was more effective at two years, more data is
1. Several landmark clinical trials have evaluated treatments for diabetic retinopathy and macular edema. The DCCT and UKPDS trials showed that intensive glucose control can significantly reduce the risk of retinopathy progression. The DRS established laser photocoagulation as an effective treatment for proliferative diabetic retinopathy, while the ETDRS defined treatment indications and techniques. The DRVS demonstrated benefits of early vitrectomy for advanced proliferative retinopathy. Recent studies of intravitreal injections showed significant vision gains compared to laser in diabetic macular edema. The DRCR Network continues to evaluate new therapies through multicenter clinical trials.
This document provides a review of literature on diabetic macular edema (DME). It summarizes key studies on the pathophysiology and treatment of DME, including the Early Treatment Diabetic Retinopathy Study (ETDRS), trials of intravitreal corticosteroids, anti-VEGF drugs, and combination therapies. Major studies discussed include DRCR.net, PACORES, RESOLVE, BOLT, RIDE, and RESTORE trials which evaluated laser photocoagulation, corticosteroids, ranibizumab, bevacizumab, and combination therapies for treating DME. The document concludes anti-VEGF drugs like ranibizumab and bevacizumab
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
The biomechanics of running involves the study of the mechanical principles underlying running movements. It includes the analysis of the running gait cycle, which consists of the stance phase (foot contact to push-off) and the swing phase (foot lift-off to next contact). Key aspects include kinematics (joint angles and movements, stride length and frequency) and kinetics (forces involved in running, including ground reaction and muscle forces). Understanding these factors helps in improving running performance, optimizing technique, and preventing injuries.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Computer in pharmaceutical research and development-Mpharm(Pharmaceutics)MuskanShingari
Statistics- Statistics is the science of collecting, organizing, presenting, analyzing and interpreting numerical data to assist in making more effective decisions.
A statistics is a measure which is used to estimate the population parameter
Parameters-It is used to describe the properties of an entire population.
Examples-Measures of central tendency Dispersion, Variance, Standard Deviation (SD), Absolute Error, Mean Absolute Error (MAE), Eigen Value
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
Debunking Nutrition Myths: Separating Fact from Fiction"AlexandraDiaz101
In a world overflowing with diet trends and conflicting nutrition advice, it’s easy to get lost in misinformation. This article cuts through the noise to debunk common nutrition myths that may be sabotaging your health goals. From the truth about carbohydrates and fats to the real effects of sugar and artificial sweeteners, we break down what science actually says. Equip yourself with knowledge to make informed decisions about your diet, and learn how to navigate the complexities of modern nutrition with confidence. Say goodbye to food confusion and hello to a healthier you!
Nano-gold for Cancer Therapy chemistry investigatory projectSIVAVINAYAKPK
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Nutritional deficiency Disorder are problems in india.
It is very important to learn about Indian child's nutritional parameters as well the Disease related to alteration in their Nutrition.
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
4. Argon study
• blue-green
argon laser
• Leaking CNV
outside the
fovea (200-
2500 microns
from FAZ)
Krypton study
• krypton red
laser
• leaking CNV
with posterior
border 1-199
microns from
FAZ
Foveal study
• new or
recurrent
CNVM under
the centre of
FAZ.
Macular Photocoagulation Study
(MPS,1979)
5. Laser photocoagulation treatment had better visual outcome compared to
observation
Extrafoveal or juxtafoveal CNVM – persisted till 5 yr
Subfoveal CNVM - persisted till 4 yr
Green argon laser (514 nm) - state-of-the-art for photocoagulation of CNV
Green 532-nm frequency-doubled Nd-YAG laser -replaced argon laser
now the standard in photocoagulation for CNV
Conclusions...
7. Subfoveal predominantly
classic CNV
Sustained VA
Stabilized contrast sensitivity
Preserved the quality of
vision
Minimally classic CNV -did
not benefit much
Occult CNV or evidence of
recent disease progression
Sustained VA
Stabilized contrast sensitivity
Preserved the quality of
vision
Conversion to more
aggressive classic
component of CNV- fewer
pts
Minimally classic CNVM
Compared SF/RF vs Placebo
SF/RF- better visual outcome
lesser conversion to
predominantly classic CNVM
VIP VIMTAP
Studies
8. • shown benefits in selected subtypes and stages of neovascular
AMD
• Now largely superseded by Anti VEGF drugs
• Remain a rational therapeutic option for selected patients in
whom VEGF inhibition is not advisable.
• Pdt as rescue therapy (with combination of an anti-VEGF
agent) –In failed anti-VEGF monotherapy
• peripapillary CNV
Current Recommendations
11. VISION year 1
• Efficacy of Pegaptanib in entire AMD
spectrum
• 4 groups
• Every 6wks for 48 wks
VISION year 2
• Efficacy of 1 yr vs 2 yr
• Treatment arm
• Sham arm
Conclusion
• efficacious at all doses tested
• FDA approved lowest dose 0.3mg
Conclusion
• Continued visual benefit in year 2
• Occult CNV- No statistically
significant benefit
VISION
0 0.3 1.0 3.0
VEGF inhibition study in ocular neovascularisation
(VISION)
12. • Macugen approved for all lesion types in neovascular AMD by
FDA,2004
• Therapeutic benefit was favourable compared with PDT monotherapy
• The chance of a statistically significant improvement in VA was
relatively low (6%)
• Due to its poorer efficacy compared with other currently available anti-
VEGF drugs, pegaptanib is no longer recommended for the treatment
of exudative AMD
Current Recommendations
13. humanised Fab fragment of a
monoclonal antibody with a high
affinity for VEGF A
Bevacizumab- long systemic retention
for metastatic CA
Ranibizumab- rapid systemic clearance
by removing the Fc fragment from the
parent molecule
High systemic safety
Ranibizumab
15. MARINA (Minimally Classic/Occult Trial of the
Anti-VEGF Antibody Ranibizumab in the
Treatment of Neovascular ARMD)
Purpose
• Efficacy of RBZ in the treatment of minimally classic/ occultCNV
Method
• 3 groups
• Monthly inj for 24 months
Conclusion
• RBZ ftreated pts had substantially better VA outcomes
• better stabilization of lesion characteristics compared to sham
0 0.3 0.5
16. MARINA study. (A) Rate
of loss or gain of visual acuity at 12
and 24 months associated with
ranibizumab, as compared with sham
injection. At 12 months, mean
increases in visual acuity were +6.5
letters in the 0.3 mg group and +7.2
letters in the 0.5 mg group, as
compared with a decrease of –10.4
letters in the sham-injection group
(p<0.001 for both comparisons). The
benefit in visual acuity was maintained
at 24 months. The average benefit
associated with ranibizumab over that
of sham injection was approximately
17 letters in each dose group at
12 months, and 20–21 letters at
24 months. (B) Mean (±SE) changes in
choroidal neovascularisation and
leakage. The mean change from
baseline in each of the
ranibizumab-treated groups differed
significantly from that in the
sham-injection group at 12 and
24 months (p<0.001 for each
comparison) in favour of ranibizumab
treatment. Printed with permission
from ref 13.
1152
17. ANCHOR (ANti-VEGF Antibody for the Treatment
of Predominantly Classic CHORoidal
Neovascularization in AMD
Purpose
• RBZ VS verteporfin PDT in predominantly classic CNV
Method
• 3 groups
• RBZ inj monthly/ PDT 3 monthly for 24 months
Conclusion
• Ranibizumab provided greater clinical benefit than
verteporfin PDT
PDT 0.3 RZ 0.5 RZ
18. ANCHOR study. Mean
(±SE) changes in the number of letters
read as a measure of visual acuity
from baseline through 12 months. The
tracking of mean changes in visual
acuity scores over time showed that
the values in each of the ranibizumab
groups were significantly superior to
those in the verteporfin group at each
month during the first year (p<0.001)
(figure 2) On average, visual acuity of
ranibizumab-treated patients increased
by +5.9 letters in the 0.3 mg group
and +8.4 letters in the 0.5 mg group
at 1 month after the first treatment
and increased further over time to a
gain of +8.5 letters in the 0.3 mg
group and +11.3 letters in the 0.5 mg
group by 12 months. By contrast, the
verteporfin group had an average loss
in visual acuity at each month after the
first month, with a mean loss of 9.5
letters by 12 months. Printed with
permission from ref 13.
19. Following MARINA
and ANCHOR trials
several studies
looked at ways to
decrease the
treatment burden
while maintaining
similar visual
gains
These trials include
PIER
EXCITE
PrONTO
SUSTAIN
HORIZON
20. PIER
Purpose
• efficacy and safety of RBZ administered monthly for 3
months and then quarterly
Method
• 3 groups
• RBZ provided VA benefits to patients with CNV
compared to sham group
Conclusion
• With the quarterly dosing - steady decline in VA
during months 4-24 compared to MARINA/ANCHOR
0.3 RZ0 0.5 RZ
21. PrONTO (Prospective OCT Imaging of Patients
with Neovascular AMD Treated with intra-Ocular
Ranibizumab)
Purpose
• OCT guided, variable dosing regimen
Method
• 3 consecutive monthly injections of 0.5 mg RBZ
• Subsequent monthly visit with OCT
• Retreatment if activity recurs
Conclusion
• VA outcomes similar to results from MARINA and ANCHOR studies
with 59% less injections being used over a period of 2 years
22. SUSTAIN
Purpose
• safety and efficacy of individualized RBZ treatment (pro re nata / PRN
regime)
Method
• 3 consecutive monthly injections of 0.3 mg RBZ
• Retreatment was administered for 9 months if
• More than 5 letter loss in VA /100 microns increase in CRT
Conclusion
• VA in patients with individualized re-treatment based on VA/OCT
assessment reached on average a maximum after the first 3 monthly
injections, decreased slightly under PRN during next 2-3 months,
which was sustained throughout the treatment period.
23. HARBOR
Purpose
• 12 month efficacy and safety of intravitreal RBZ 0.5mg and
2mg administered monthly and on PRN basis
Method
• 4 groups
• 0.5mg monthly/0.5mg PRN/2 mg monthly/2mg PRN
conclusion
• All groups demonstrated clinically meaningful visual
improvement and improved anatomic outcomes
• PRN group requiring approximately 4 fewer injections
• No additional benefit of higher dose (2mg) RBZ
•The HARBOR study is the only trial that has included SD-OCT monitoring into a PRN
regimen compared with monthly treatment
24.
25. SAILOR (Safety Assessment of Intravitreal
Lucentis for AMD)
Purpose
• safety and efficacy of intravitreal RBZ in a large population
Method
• Subjects divided into 2 cohorts
• Intravitreal RBZ is safe and well tolerated
Conclusion
• Although the risks of arterial thrombolic events related to
RBZ are low, ophthalmologists should be aware of these
risks to appropriately educate and treat patients
26. HORIZON (Extension Trial)
Purpose
• long-term safety and efficacy of multiple intravitreal
RBZ injections
Method
• two-year extension study for 853 patients who
completed the ANCHOR, MARINA
• Multiple RBZ injections were well tolerated for ≥4
years.
Conclusion
• The incidence of serious ocular and non-ocular
adverse events was low.
27.
28.
29. monthly intravitreal injections until maximum VA is achieved
for three consecutive monthly assessments
monitored monthly for VA
resume treatment when monitoring indicates loss of
VA due to wet AMD
Monthly injections should then continue until stable
VA is reached again for three consecutive monthly
assessments
Recommendations based on above studies
approved by the FDA (July 2006)for all
lesion types in NVAMD
Ranibizumab
0.5 mg
[ANCHOR, MARINA, PIER, EXCITE, HARBOR and CATT study data (evidence level I) as well as the SECURE and HORIZON
study data (evidence level II),bjo.bmj.com]
31. SANA (Systemic bevacizumab (Avastin®) therapy
for Neovascular Age–related macular
degeneration)
Purpose
• safety, efficacy, and durability of bevacizumab for the
treatment of subfoveal CNV
Method
• intravenous infusion of 5mg/kg bevacizumab followed
by 1 or 2 additional doses at 2 weeks interval
Conclusion
• Systemic bevacizumab therapy for neovascular AMD
was well tolerated and effective
• Couldn’t be tried in large group due to systemic A/E
32. ABC(Avastin® (Bevacizumab) for Choroidal
neovascularisation)
Purpose
• efficacy and safety of intravitreal bevacizumab in neovascular AMD
Method
• 2 groups
• Intravitreal bevacizumab 1.25mg, 3 loading dosesat 6 weeks
interval
• Standard treatment in the form of PDT or intravitreal pegaptinib
Conclusion
• 1.25mg bevacizumab was superior to standard treatment
34. • RBZ VS BVZ when administered monthly or as
needed for 2 years
• RBZ and BVZ had equivalent effects on VA when administered
according to same schedule over a 2 year period.
• Treatment as needed resulted in less gain of VA whether instituted
at enrolment or after 1 year of monthly treatment.
• There was no difference in safety profiles of these drugs together
RBZ monthly for 1 yr
Monthly
1 yr
Variable
dosing
BVZ monthly for 1 yr
Monthly
1 yr
Variable
dosing
RBZ monthly for 2 yr BVZ monthly for 1 yr
CATT (Comparison of Age-related Macular
Degeneration Treatments Trials)
35.
36. IVAN (Inhibit VEGF in Age-related choroidal
Neovascularisation)
Purpose
• efficacy and safety of RBZ and bevacizumab intravitreal injections
to treat neovascular AMD
Method
• 4 groups: RBZ or bevacizumab, given either every month
(continuous) or as needed (discontinuous), with monthly review.
Conclusion
• VA with continuous and PRN treatment were equivalent
• Cost of RBZ treatment was 6-7 times more than bevacizumab
treatment.
• Safety profile was similar in all regimens
37. VEGF Trap-Eye (aflibercept)
fusion protein
Binds to all vegf-A isoforms and vegf-B, placental growth factor (PlGF)
binding affinity of aflibercept is 100 times higher
38. VIEW 1 (US) and VIEW 2 (Canada,
South America, Europe, Asia, Australia)
Purpose
• To compare monthly and every 2-month dosing of intravitreal VEGF trap-
eye with monthly RBZ
Method
• 4 groups
• Aflibercept 0.5/2 mg monthly, 2mg 2 monthly after 1st 3 inj, RBZ 0.5mg
monthly
Conclusion
• similar efficacy as monthly RBZ.
• 2 monthly injections reduced the risk of infection from monthly injections
39. Recommendations based on above studies
approved by the FDA (2012)for all
lesion types in NVAMD
Aflibercept
2.0mg
monthly injections for the initial 3 months
fixed dosing every 8 weeks
After 12 months of treatment, the injection
intervals may be prolonged
40. First single-chain antibody fragment
in ophthalmology
small molecular size(26kDa)
Target VEGF A
Dose- 6 mg
FDA approval in 2019
HAWK and HARRIER trial
showed success in 12 wkly
regimen
BEOVU
Brolucizumab